Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients-Reference-Cited by-同舟云学术

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients

Published:2007-12 Issue:12 Volume:17 Page:1057-1064
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Giusti Betti,Gori Anna Maria,Marcucci Rossella,Saracini Claudia,Sestini Ilaria,Paniccia Rita,Valente Serafina,Antoniucci Davide,Abbate Rosanna,Gensini Gian Franco

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference30 articles.

1. Prothrombotic and antithrombotic pathways in acute coronary syndrome;Selwyn;Am J Cardiol,2003

2. Subacute stent thrombosis: evolving issues and current concepts;Mak;J Am Coll Cardiol,1996

3. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting;Bhatt;J Am Coll Cardiol,2002

4. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation;Yusuf;N Engl J Med,2001

5. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically;Buchanan;Can J Cardiol,1995

Cited by 196 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention;Pharmacogenomics;2024-05-02

2. Genetic Analysis of Cytochrome P450 Polymorphisms in Drug-responsive and Drug-refractory Epileptic patients in Telangana;The Open Neurology Journal;2023-12-26

3. Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention;The American Journal of Cardiology;2023-09

4. Influence of Genetic and Epigenetic Factors of P2Y12 Receptor on the Safety and Efficacy of Antiplatelet Drugs;Cardiovascular Drugs and Therapy;2022-08-09

5. Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients;Scientific Reports;2022-04-13